References

Retrospective cohort study of predictors of loss to follow up among adolescents and young adults living with HIV on ART in Dar es Salaam, Tanzania, 2015-2019

10.1186/s12879-025-11157-1 · 2025 · External reference

High attrition before and after ART initiation among youth (15–24 years of age) enrolled in HIV care

10.1097/qad.0000000000000054 · 2014 · External reference

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

10.1016/s2352-3018(20)30340-4 · 2021 · External reference

Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment

10.1097/qad.0000000000003025 · 2022 · External reference

Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial

10.1038/s41591-025-04041-7 · 2026 · External reference

10.1016/s2352-3018(23)00300-4

10.1016/s2352-3018(23)00300-4 · 2024 · External reference

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

10.1016/s2352-3018(24)00344-8 · 2025 · External reference

10.1016/s2352-3018(23)00301-6

10.1016/s2352-3018(23)00301-6 · 2024 · External reference

Acceptability and tolerability of long-acting injectable cabotegravir–rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial

10.1016/s2352-3018(25)00241-3 · 2026 · External reference

Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir–rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study

10.1016/s2352-3018(25)00242-5 · 2026 · External reference

Real world virologic outcomes in patients with elevated body mass index receiving long acting cabotegravir/rilpivirine

10.1093/cid/ciae579 · 2025 · External reference

Cabotegravir + rilpivirine long-acting injections for HIV treatment in the US: real world data from the OPERA cohort

10.1007/s40121-023-00890-2 · 2023 · External reference

Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror phase 3 results

10.1093/jac/dkae308 · 2024 · External reference

Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

2023 · External reference

Efficacy and safety of cabotegravir-rilpivirine in PLWH: a real-world study

10.3390/v17111417 · 2025 · External reference

Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the Injectable Antiretroviral Therapy Feasibility Study (JABS)

10.1111/hiv.13647 · 2024 · External reference

Experience of treatment with long-acting injectable cabotegravir/rilpivirine (LA iCAB/RPV) in viremic young patients with perinatally acquired HIV with adherence challenges: a five-case series

10.1016/j.ijid.2025.108104 · 2025 · External reference

Off-label use of long-acting injectable antiretroviral therapy: a single center retrospective review of youth living with HIV with detectable HIV RNA starting injectable therapy

10.1093/jpids/piae033 · 2024 · External reference

Efficacy, safety and retention in care among adolescents and youth with HIV on long-acting injectable cabotegravir/rilpivirine treatment: real-world observational cohort outcomes

10.1097/inf.0000000000004742 · 2025 · External reference

Long-acting injectable antiretroviral therapy in South African adolescents and young adults—week 48 results from the AFINAty Study

10.1097/qai.0000000000003973 · 2026 · External reference

The Faces Pain Scale—revised: toward a common metric in pediatric pain measurement

10.1016/s0304-3959(01)00314-1 · 2001 · External reference

Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial

10.1016/s2352-3018(20)30106-5 · 2020 · External reference

Development and validation of a liquid chromatographic–tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue

10.1016/j.jpba.2016.08.016 · 2016 · External reference

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

10.1016/s2352-3018(21)00185-5 · 2021 · External reference

Virological history predicts non-sustained viral suppression with long-acting cabotegravir and rilpivirine therapy, independent of pharmacokinetic parameters

10.1093/cid/ciae475 · 2025 · External reference

Transient viremia among people with HIV receiving injectable cabotegravir plus rilpivirine

10.1089/aid.2024.0083 · 2025 · External reference

Extrapolation of adult data and other data in pediatric drug-development programs

10.1542/peds.2010-3487 · 2011 · External reference

Bictegravir/emtricitabine/tenofovir alafenamide for HIV-1: what is the hidden potential of this emerging treatment?

2023 · External reference

Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women

10.1056/nejmoa2407001 · 2024 · External reference

Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons

10.1056/nejmoa2411858 · 2025 · External reference